- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Blueprint Medicines Corp (2L9)"Blueprint Medicines Corp stock price live, this page displays NASDAQ BPMC stock exchange data. View the BPMC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Blueprint Medicines Corp real time stock price chart below.
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 89.2200.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is ""BPMC.""
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)"
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 89.2200.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is ""BPMC.""
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)"
89.2200
-0.2800(-0.31%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
89.2200
89.2200
52 wk Range
67.0000
110.9000
2L9 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
89.220089.2200
52 wk Range
67.0000110.9000
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
Unlock2L9 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Price Target
125.5800
Upside
+32.0782%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
- JPMorgan is out with its 2025 outlook for biotech stocks
- Investing.com
Pro
- JPMorgan is out with its 2025 outlook for biotech stocks
- Investing.com
Pro
Blueprint Medicines Corp Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Compare 2L9 to Peers and Sector
Metrics to compare | 2L9 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2L9PeersSector | |
|---|---|---|---|---|
P/E Ratio | −47.2x | −3.5x | −0.7x | |
PEG Ratio | −0.62 | 0.06 | 0.00 | |
Price/Book | 19.3x | 2.2x | 2.6x | |
Price / LTM Sales | 13.9x | 72.7x | 3.2x | |
Upside (Analyst Target) | - | 403.4% | 44.1% | |
Fair Value Upside | Unlock | 9.3% | 8.2% | Unlock |
FAQ
What Is the Blueprint Medicines Corp (2L9) Stock Price Today?
The Blueprint Medicines Corp stock price today is 89.22
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is "2L9."
What Is the Blueprint Medicines Corp Market Cap?
As of today, Blueprint Medicines Corp market cap is 5.71B.
What is Blueprint Medicines Corp Earnings Per Share?
The Blueprint Medicines Corp EPS is -2.06.
From a Technical Analysis Perspective, Is 2L9 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.